Hormone Therapy in Prostate Cancer: LHRH Antagonists versus LHRH Analogues
- 30 September 2004
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 46 (3) , 279-284
- https://doi.org/10.1016/j.eururo.2004.05.006
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Phase II Study of Abarelix Depot for Androgen Independent Prostate Cancer Progression During Gonadotropin-Releasing Hormone Agonist TherapyJournal of Urology, 2003
- A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate CancerJournal of Urology, 2002
- A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancerUrology, 2001
- Luteinizing hormone–releasing hormone antagonists in prostate cancerUrology, 2001
- THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCERJournal of Urology, 2001
- Gonadotropin-releasing hormone antagonistsCurrent Opinion in Endocrinology, Diabetes and Obesity, 2000
- HORMONE-REFRACTORY PROSTATE CANCER CELLS EXPRESS FUNCTIONAL FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR)Journal of Urology, 1999
- Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot lhrh analogueCancer, 1991
- Prostate—an extrapituitary source of follicle‐stimulating hormone (FSH): Occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodentsThe Prostate, 1991
- Immunocytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostatesBritish Journal of Cancer, 1990